Re: "mounting concern" about the profits of processed food & tobacco companies, here you are also the 2018 classic of the genre: > Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?’ https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patie...
The actual report (not linked to by CNBC of course) says The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies, particularly in certain diseases where it is possible to cure a large proportion of the prevalent…
or innovators dilemma upsets or forces the incumbents. the transformer (attention is all you need) model paper did release in 2017 and Google did nothing about it until OpenAI forced their hand
awaiting this happening to pharma as well as new technology reduces the barrier to entry for innovators